Alex Meraz
@nephroguy.bsky.social
Academic Nephrologist in Winnipeg 🇨🇦. Onconeph and Critical care neph FTW!
In the SNAP trial, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality in patients with methicillin-susceptible Staphylococcus aureus bacteremia and had fewer nephrotoxic effects. Read the full trial results: https://nej.md/4vL0M6m
In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months. Full phase 3 FIND-CKD trial results: https://nej.md/4wWOFV4 #ERA26
Unlike COMPASS, TRACK demonstrates rivaroxaban doesn’t have the same CV benefit in CKD jamanetwork.com/journals/jam... Simultaneous pubs from #ERA26
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.
jamanetwork.com
Final GFR results from Atrasentan (ALIGN) in the Lancet Underwhelming to me - the Flozin + Atrasentan looks pretty good OTOH www.thelancet.com/journals/lan... Simulpubs from #ERA26
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
Atrasentan reduced proteinuria and preserved kidney function after 2·5 years. This effect was present with or without concomitant SGLT2 inhibitor use. Atrasentan was well tolerated.
thelancet.com
And FIND CKD is live already on NEJM www.nejm.org/doi/full/10.... #ERA26
Finerenone in Persons with Chronic Kidney Disease without Diabetes | NEJM
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD)...
nejm.org
Another #ERA26 simulpub Effect of empa/finerenone on BP, yet another splice from CONFIDENCE www.ahajournals.org/doi/10.1161/... (If you want a BP effect, use Spiro)
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure | Hypertension
BACKGROUND: This secondary analysis of the CONFIDENCE (combination effect of fInerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint) trial…
ahajournals.org
Cancer Incidence in People With Glomerular Disease: A Population-Level Study bit.ly/4smBPMv (OPEN ACCESS)
The big experiment failed Giving bonuses and penalizing for performance to increase home dialysis and transplant did nothing. An RCT jamanetwork.com/journals/jam... in JAMA health forum
#RenalPath: Diffuse granular capillary wall staining for phospholipase A2 receptor (PLA2R). PLA2R staining is positive in approximately 70% of patients with clinically idiopathic membranous nephropathy (immunofluorescence microscopy, PLA2R). bit.ly/2xVkJzs (FREE)
@hswapnil.medsky.social @kidneyboy.bsky.social What’s the name of the nephrology song you play at the end of the podcast?
The second sibeprenlimab paper in @nejm.org (At least we gave it an oral at #KidneyWk unlike the poster for the phase 2 data in 2023!) www.nejm.org/doi/full/10....
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial | NEJM
The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and...
nejm.org
And it’s live Iptacopan in C3GN makes it to @thelancet.com www.thelancet.com/journals/lan... #NephSky
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study
Iptacopan showed a statistically significant, clinically meaningful proteinuria reduction in addition to RAAS inhibitors and immunosuppression at 6 months. Iptacopan was well tolerated with an accepta...
thelancet.com
Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · 10mo agoAnd here’s her fabulous talk on the C3GN subject youtu.be/Fo6J__RgWA0?... #GlomCon #NephSky
Amazing to me that a seemingly acute event is either A) has long-term sequellae despite being apparently resolving or B) a dramatic and early presentation of profound endothelial disease
American Journal of Hypertension@amjhypertension.bsky.social · last yr.Effect of losartan on endothelial function in women with history of #preeclampsia 🔗 academic.oup.com/ajh/article/... 🔓 #OpenAccess #Free
Way scarier story. Stories. www.nytimes.com/2025/06/13/t... (Gift link)
They Asked an A.I. Chatbot Questions. The Answers Sent Them Spiraling.
nytimes.com
Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last yr.Hilarious (and sobering) essay on the use of AI in medical research & manuscript writing Read the whole thing! John Daugirdas has been on the cutting edge of tech in meded before #MedEd was thing onlinelibrary.wiley.com/doi/10.1111/... #MedSky #NephSky
Sibeprenlimab in IgA Nephropathy #ERA25 * Data presented is the 9-month reduction in proteinuria
The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....
In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: nej.md/4jEVbbk #ERA25 #MedSky #Nephrology
@kevinyau.bsky.social GLP1 agonist master Jedi presenting at #ERA25. 💉GLP1 agonist reduce ED visits and hospitalizations!!! 📉Awesome methods. Best of the session: 💊DDP4 for comparison, IPTW, ICES data. Ticking all the right boxes (EPI nerd). 💊Only 40% on SGLT2i!!! We should flozinate more!!!
